Brainsway

BrainsWay to Report Third Quarter Financial Results on November 16, 2022

Retrieved on: 
Wednesday, November 2, 2022
Awareness, Deep, TMS, Technology, Psychiatry, Health, Tic disorder, Addiction, Company, Transcranial magnetic stimulation, FDA, News, Brainsway, Video game, Pharmaceutical industry

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders.

Key Points: 
  • BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders.
  • The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives.
  • BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy.
  • Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS.

BrainsWay Appoints Dr. Colleen A. Hanlon as Vice President of Medical Affairs

Retrieved on: 
Tuesday, November 1, 2022
Awareness, Neuromodulation, Failure, Medical Affairs Bureau, CEO, National Center for Health Research, National Institutes of Health, Health, Knowledge, Neuroscience, Wake Forest, Transcranial magnetic stimulation, News, Brainsway, Faculty, Legislation, GLOBE, Research, National Institute, Psychiatry, NIH, U.S. Securities and Exchange Commission, Addiction, Ministry of Education (Malaysia), Safety, TMS, Duke University, Technology, TASE, NASDAQ, Tic disorder, Private Securities Litigation Reform Act, Company, FDA, Review, Deep, Wake Forest University School of Business, Rehabilitation, Wake Forest School of Medicine, Insurance, Medical device, Medicine, Pharmaceutical industry, Medicare, Medicine

and JERUSALEM, Nov. 01, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Colleen A. Hanlon, Ph.D. as Vice President of Medical Affairs.

Key Points: 
  • and JERUSALEM, Nov. 01, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Colleen A. Hanlon, Ph.D. as Vice President of Medical Affairs.
  • I am delighted to welcome Dr. Hanlon to BrainsWay.
  • This is a new era in treatment options for mental healthcare, and BrainsWay is leading the way.
  • After receiving a Ph.D. in neurobiology from Duke University in 2005, Dr. Hanlon quickly ascended through the faculty ranks in academia.

BrainsWay Launches Social Media Sweepstakes in Observance of Depression Awareness Month

Retrieved on: 
Wednesday, October 12, 2022
News, LinkedIn, U.S. Securities and Exchange Commission, Insurance, Uncertainty, Deep, TMS, Review, Education, NASDAQ, Lists of diseases, Depression, Research, Mental health, TASE, Facebook, Addiction, Awareness, Technology, Knowledge, Private Securities Litigation Reform Act, Company, Health, Legislation, CEO, Airbnb, Moment, Social media, Patient safety, Tic disorder, Transcranial magnetic stimulation, GLOBE, Failure, Brainsway, FDA, COVID-19, Psychiatry, OCD, Medicine, Pharmaceutical industry, Instagram, Medicare, Sweepstake

Participants on social media can enter starting Friday, Oct. 14 and continue throughout the month of October for a chance to win a $2,000 Airbnb gift card.

Key Points: 
  • Participants on social media can enter starting Friday, Oct. 14 and continue throughout the month of October for a chance to win a $2,000 Airbnb gift card.
  • We want to create a world where mental health is within reach for all, said BrainsWay President and CEO Christopher von Jako, Ph.D.
  • The Dont Miss Another Moment Sweepstakes demonstrates BrainsWays commitment to raising awareness and education around mental health, in observance of Depression Awareness Month.
  • It allows social media users to learn from those living with mental health conditions and helps alleviate the stigma of seeking help.

BrainsWay and NOCD Launch Collaboration to Increase Awareness of OCD Treatments

Retrieved on: 
Tuesday, October 11, 2022
Quality of life, News, U.S. Securities and Exchange Commission, Caregiver, Insurance, ERP, Deep, TMS, Review, Policy, Obsessive–compulsive disorder, NASDAQ, Cigna, Patient, Obsessions, Income, Lists of diseases, Research, Psychotherapy, Mental health, TASE, Response, Blue Cross Blue Shield Association, Technology, Addiction, Knowledge, WHO, Private Securities Litigation Reform Act, Partnership, Trial of the century, Company, Tricare, Psychiatry, World, Health, Legislation, American Journal, CEO, Awareness, World Health Organization, Tic disorder, Transcranial magnetic stimulation, GLOBE, Failure, Brainsway, FDA, The American Journal of Psychiatry, Compulsions, OCD, Pharmaceutical industry, Health insurance, Medicare

This collaboration signifies an alignment of our collective goal to raise awareness and facilitate access to clinically proven treatment options for OCD.

Key Points: 
  • This collaboration signifies an alignment of our collective goal to raise awareness and facilitate access to clinically proven treatment options for OCD.
  • Stephen Smith, Cofounder and CEO of NOCD, said,NOCD is proud to partner with BrainsWay to raise OCD awareness and to help our community access additional OCD treatment interventions when needed.
  • BrainsWays collaboration with NOCD will help patients find the treatments they urgently need with access to ERP therapists and Deep TMS providers nationwide.
  • BrainsWay and NOCD will work together to increase awareness about OCD and the lifesaving treatments of both companies.

BrainsWay CEO Christopher von Jako Named Honorary Chair of NAMIWalks Silicon Valley

Retrieved on: 
Tuesday, September 20, 2022
Curse of Coogan's Bluff, Health, National Alliance, Addiction, TMS, Mental disorder, FDA, Psychiatry, Brainsway, San Francisco Giants, Transcranial magnetic stimulation, TASE, Tic disorder, National Alliance on Mental Illness, Company, News, NAMI, Mental health, Patient, Wellness, CEO, Technology, Lists of diseases, San Francisco, Deep, Doctor of Philosophy, Walking, NASDAQ, EAP, GLOBE, Awareness, Pharmaceutical industry, Medicine, Silicon

and JERUSALEM, Sept. 20, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a world leader in advanced and noninvasive treatment for brain disorders, announced that its President and CEO, Christopher von Jako, PhD, was named an honorary cochair of NAMIWalks Silicon Valley .

Key Points: 
  • and JERUSALEM, Sept. 20, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a world leader in advanced and noninvasive treatment for brain disorders, announced that its President and CEO, Christopher von Jako, PhD, was named an honorary cochair of NAMIWalks Silicon Valley .
  • I am inspired by the work NAMI does for mental health around the country, and I am looking forward to joining forces at the NAMI Silicon Valley walk, said Dr. von Jako.
  • Rovina Nimbalkar, Executive Director of NAMI Santa Clara County, said, We are honored to have Christopher von Jako as our honorary chair for NAMIWalks Silicon Valley and we are excited about our collaboration with BrainsWay.
  • NAMIWalks Silicon Valley is our biggest fundraiser, and after two years we are going to walk in person.

BrainsWay Announces Significant Private Insurance Coverage from Cigna Corporation for the Treatment of OCD Utilizing Deep TMS™

Retrieved on: 
Wednesday, September 14, 2022
Income, Health, Yale–Brown Obsessive Compulsive Scale, Addiction, TMS, Cigna, Policy, MD, FDA, Brainsway, Y-BOCS, Transcranial magnetic stimulation, Disease, Brain, Food, Psychiatry, TASE, Tic disorder, U.S. Securities and Exchange Commission, World Health Organization, Knowledge, Company, Legislation, World, News, Review, Private Securities Litigation Reform Act, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, OCD, Technology, Quality of life, Disorder, Obsessions, Lists of diseases, Blue Cross Blue Shield Association, Health insurance, Deep, Leadership, Doctor of Philosophy, Tricare, Insurance, NASDAQ, Compulsions, WHO, De novo, Ageing, Research, Market access, GLOBE, Awareness, Failure, Medical device, Pharmaceutical industry, Medicare

Cigna will be issuing an updated revision to its TMS medical coverage policy effective September 15, 2022extending coverage to patients aged 18 and older diagnosed with OCD.

Key Points: 
  • Cigna will be issuing an updated revision to its TMS medical coverage policy effective September 15, 2022extending coverage to patients aged 18 and older diagnosed with OCD.
  • OCD is a difficult to treat disease, and almost half of the patients with OCD are treatment-resistant.
  • This positive coverage decision supplements the growing body of compelling clinical evidence supporting the treatment of OCD with our Deep TMS H7 Coil.
  • The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives.

Hudson Mind Introduces TMS Treatments

Retrieved on: 
Tuesday, September 13, 2022
Gaps, TMS, Neuronetics, Brain, FDA, Transcranial magnetic stimulation, Brainsway, Psychotherapy, Neurology, SAINT, Patient, Mental health, OCD, Stanford University, Anxiety, Insurance, Pain management, Anesthesiology, Dysthymia, PTSD, Depression, Medicine, High-performance plastics, Pharmaceutical industry

NEW YORK, Sept. 13, 2022 /PRNewswire/ --Hudson Mind today announced its Transcranial Magnetic Stimulation (TMS) offering.

Key Points: 
  • NEW YORK, Sept. 13, 2022 /PRNewswire/ --Hudson Mind today announced its Transcranial Magnetic Stimulation (TMS) offering.
  • Launched in 2022 as the mental health division of Hudson Health (formerly Hudson Medical Group) Hudson Mind has pioneered a groundbreaking approach to treating symptoms of depression, anxiety, and PTSD.
  • Hudson Mind uses NeuroStar's TMS technology, as well as BrainsWay's Deep TMS technology.
  • Hudson Mind's treatments include Dual Sympathetic Blocks for anxiety and PTSD, ketamine infusions for anxiety and depression, and advanced Transcranial Magnetic Stimulation (TMS) for depression and OCD.

BrainsWay to Present at the H.C. Wainwright Annual Global Investment Conference

Retrieved on: 
Wednesday, August 31, 2022
News, Tic disorder, Addiction, Transcranial magnetic stimulation, Lists of diseases, Technology, Psychiatry, Deep, TMS, Health, Brainsway, Company, Awareness, FDA, Security (finance), Pharmaceutical industry

Investors interested in meeting with the BrainsWay management team during the conferences should contact their H.C. Wainwright representative.

Key Points: 
  • Investors interested in meeting with the BrainsWay management team during the conferences should contact their H.C. Wainwright representative.
  • BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders.
  • BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy.
  • Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS.

BrainsWay Receives New FDA Clearance for Treating Depression and Anxious Depression

Retrieved on: 
Monday, August 29, 2022
Addiction, Deep, Technology, Heart rate, Observation, Psychiatry, Research, TMS, Legislation, National Institute, Regulation of tobacco by the U.S. Food and Drug Administration, WHO, Grammatical mood, Appetite, Brain, Awareness, Insurance, Private Securities Litigation Reform Act, NASDAQ, Transcranial magnetic stimulation, Lists of diseases, Panic, Food, Anxiety, Tremor, Nervous, Insomnia, Review, Common, U.S. Securities and Exchange Commission, Depression, Thought, GLOBE, Perspiration, Company, FDA, News, Failure, Tic disorder, MDD, World, Knowledge, TASE, Mental health, NIMH, Health, COVID, Brainsway, Patient, World Health Organization, Pharmaceutical industry, Medical imaging, Risk management, Medicare

The FDAs grant of clearance was based on its review of successful results from a randomized, double-blind, controlled multicenter trial completed by the Company.

Key Points: 
  • The FDAs grant of clearance was based on its review of successful results from a randomized, double-blind, controlled multicenter trial completed by the Company.
  • With this new clearance, there is no need to upgrade or add software to systems currently installed in the field.
  • BrainsWay will be implementing a training program in the coming months to educate customers on using the Deep TMS H7 Coil to treat depression within the new FDA clearance.
  • Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction.

Indiana Center for Recovery Unveils BrainsWay Deep TMS™

Retrieved on: 
Tuesday, August 16, 2022
FDA, Multimedia, Mental health, Selective serotonin reuptake inhibitor, Technology, Lists of diseases, Deep, Patient, Company, TMS, Partnership, Tic disorder, Awareness, News, Brainsway, Goal, Mental, Eating recovery, Transcranial magnetic stimulation, Health, OCD, Pharmaceutical industry

SOUTH BEND, Ind., Aug. 16, 2022 /PRNewswire/ -- Indiana Center for Recovery—the largest mental health and addiction treatment provider in the state—announces its partnership with BrainsWay, a leader in noninvasive neurostimulation treatments for mental health disorders. This technology, combined with custom care plans from Indiana Center for Recovery, will bring recovery and relief through clinically demonstrated, painless treatments that can be highly effective when other treatment modes have failed.

Key Points: 
  • BrainsWay's Deep TMS treatment is based on novel breakthrough technology that targets brain areas for increased stimulation and activity.
  • Boosting care for patients with substance use and mental health disorders, Indiana Center for Recovery will use Deep TMS within holistic treatment paths unique to each patient.
  • New patients will see how Indiana Center for Recovery's experts and compassionate professionals use Deep TMS to promote true wellness in South Bend and beyond.
  • Since 2016, Indiana Center For Recovery has pushed patient outcomes through expert staff, high-end facilities, and scientifically sound protocols for patient-centered recovery.